A man with long-standing type 1 diabetes underwent transplant with UP421 gene-edited islet cells designed to avoid rejection. Even without immunosuppression, the patient remained free of an immune ...

RA patients on upadacitinib and methotrexate showed robust antibody and T-cell responses to the recombinant zoster vaccine over 60 weeks. The vaccine maintained a satisfactory humoral response in 71.4 ...

Scientists have found a way to transform hard-to-treat tumors into targets for the immune system. Using two protein stimulators, they activated strong T-cell and B-cell responses and built immune ...

In a paradigm breaking study, Dr. Pavan Reddy, director of the Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine (BCM) and his team, in collaboration with Drs. Arul Chinnaiyan, S ...

Antigen presenting cells capture tumour antigen within the tumour microenvironment and migrate to tumour-draining lymph nodes where they prime tumour-reactive T cells. Tumour-reactive T cells then ...

Immune checkpoint inhibitors have reshaped cancer treatment over the past decade, but the same immune activation that shrinks tumors can also turn against healthy tissue, including the brain. A ...

Durable complete responses with CAR-NK + Rituximab in patients who failed current standards of care in Waldenstrom’s Non-Hodgkins lymphoma (NHL). Long-term evaluable patients demonstrate ongoing ...

MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (allo-iNKT) cell therapies to restore immune balance and treat ...

In patients with severe obesity, the recombinant influenza vaccine yields stronger short-term antibody responses than the egg-based standard-dose vaccine, with no safety concerns noted.

Antibody therapeutics are laboratory-made proteins designed to work like the body's natural antibodies. They are widely used ...